It appears the lot differences resulted in exposure differences. Small pharma companies generally have shitty quality control compared to bigger companies. A less potent, older lot could be the explanation. Thoughts ?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.